Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2018

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial

This open-label trial at Johns Hopkins University investigated whether direct-acting antiviral prophylaxis with grazoprevir/elbasvir (with or without sofosbuvir) could prevent hepatitis C virus infection in noninfected recipients of kidneys from HCV-infected donors. The study aimed to expand the donor pool by safely utilizing HCV-infected organs.
C. Durand; M. Bowring; Diane M. Brown; Michael A. Chattergoon; G. Massaccesi; Nichole Bair; R. Wesson; A. Reyad; F. Naqvi; D. Ostrander; J. Sugarman; D. Segev; M. Sulkowski; N. Desai· Annals of Internal Medicine· 2018· DOI 10.7326/M17-2871

The core problem

End-stage kidney disease affects over 420,000 persons in the United States requiring hemodialysis, with a mortality rate of 169 per 1000 patient-years compared to 30 per 1000 patient-years for transplant recipients. Kidney transplantation offers a survival benefit, but organ shortage is severe: waiting times can reach 10 years, and more than 50% of candidates die before transplantation. Kidneys from hepatitis C virus (HCV)-infected donors are underutilized; between 2005 and 2014, 2,698 such kidneys were discarded in the U.S. Despite a 2.9-fold higher discard rate, transplantation from HCV-infected donors provides a survival benefit compared with remaining on dialysis. The advent of direct-acting antiviral (DAA) agents with high cure rates has renewed interest in HCV D+/R- transplantation. The objective of this study was to explore the feasibility and tolerability of grazoprevir/elbasvir (GZR/EBR) with or without sofosbuvir (SOF) prophylaxis to prevent HCV infection in noninfected recipients of kidneys from HCV-infected donors.

Innovation

This was an open-label, single-center, nonrandomized trial at Johns Hopkins University (EXPANDER; ClinicalTrials.gov: NCT02781649). Eligible recipients were kidney transplant candidates on the deceased-donor waiting list, aged ≥50 years, on dialysis or with GFR <15 mL/min/1.73 m² for ≥90 days, HCV antibody and RNA negative, without HCV risk factors other than hemodialysis, and without living donors. Donors were aged 13–50 years, HCV nucleic acid test positive, with terminal serum creatinine <265 µmol/L, projected cold ischemia time <36 hours, and no chronic histologic changes on preimplantation biopsy. Recipients received oral GZR 100 mg/EBR 50 mg before surgery. Postexposure prophylaxis depended on donor HCV genotype: for genotype 1a without NS5A RASs, 1b, or 4, GZR/EBR continued for 12 weeks; for genotype 1a with NS5A RASs, ribavirin was added for 16 weeks; for genotype 2 or 3, SOF 400 mg/d was added for 12 weeks. Immunosuppression included induction with methylprednisolone and rabbit antithymocyte globulin, and maintenance with tacrolimus, mycophenolate mofetil, and prednisone. Prophylaxis for other infections included trimethoprim-sulfamethoxazole, valganciclovir, and clotrimazole. Recipient HCV RNA was monitored at predefined intervals, and HCV-specific CD8+ T-cell responses were assessed by IFN-γ ELISpot. The primary safety endpoint was the incidence of adverse events.
Introduction
End-stage kidney disease affects over 420,000 persons in the United States requiring hemodialysis, with a mortality rate of 169 per 1000 patient-years compared to 30 per 1000 patient-years for transplant recipients. Kidney transplantation offers a survival benefit, but organ shortage is severe: waiting times can reach 10 years, and more than 50% of candidates die before transplantation. Kidneys from hepatitis C virus (HCV)-infected donors are underutilized; between 2005 and 2014, 2,698 such kidneys were discarded in the U.S. Despite a 2.9-fold higher discard rate, transplantation from HCV-infected donors provides a survival benefit compared with remaining on dialysis. The advent of direct-acting antiviral (DAA) agents with high cure rates has renewed interest in HCV D+/R- transplantation. The objective of this study was to explore the feasibility and tolerability of grazoprevir/elbasvir (GZR/EBR) with or without sofosbuvir (SOF) prophylaxis to prevent HCV infection in noninfected recipients of kidneys from HCV-infected donors.

Why it matters

This proof-of-concept study demonstrates that DAA prophylaxis with GZR/EBR with or without SOF can prevent HCV transmission from HCV-infected donors to noninfected kidney transplant recipients. The absence of HCV viremia and lack of HCV-specific T-cell responses support the efficacy of prophylaxis. These findings are consistent with previous case reports and suggest a strategy to expand the donor pool by utilizing HCV-infected organs. However, limitations include the small sample size, nonrandomized design, and short follow-up. The optimal duration and regimen of prophylaxis remain to be determined. The results warrant larger trials to confirm efficacy and safety, and to assess long-term outcomes. If validated, this approach could significantly reduce waitlist mortality by increasing access to transplantation.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…